Beijing Botewike Biotechnology

Beijing Botewike Biotechnology is a Chinese biotechnology company focused on the development and commercialization of recombinant protein therapeutics, specifically recombinant botulinum toxin products. The company's lead candidate, BT001, is an injectable recombinant botulinum toxin type A that acts as a SNAP-25 inhibitor. BT001 is currently in Phase 1/2 clinical development for cosmetic indications such as moderate-to-severe glabellar lines and therapeutic indications including adult upper limb spasticity. Headquartered in the Daxing Bio-medicine Industry Base within Beijing's Zhongguancun Science Park, the company is establishing a 150 million RMB industrialization facility capable of producing 2 million vials of recombinant botulinum toxin annually.